Teva believes that it can file on the one year data. Of course, they may be wrong. Any delay that shortens the time between thrice-weekly Copaxone launch and generics entry is going to reduce the transition portion.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.